Updates on urinary tract infection management in young children

Dr SN Wong, Consultant, Department of Paediatrics and Adolescent Medicine, Tuen Mun Hospital, Hong Kong

This brief communication aims to alert fellow paediatricians about the recent changes in management guidelines of urinary tract infection (UTI) in young children.

The traditional concept in the 1990’s was that UTI often signals an underlying urologic abnormality, especially vesicoureteral reflux (VUR) or obstructive uropathy, which would cause UTI recurrence and renal scarring, leading to long term complications such as chronic kidney disease, hypertension, or complications during pregnancy. Guidelines in that era focused on universal imaging with ultrasound and voiding cystourethrogram, and antibiotic prophylaxis for VUR.\(^1,2\)

During the last decade, it was realized that most "renal scars" were in fact congenital dysplasia associated with gross VUR as part of the CAKUT spectrum (Congenital Anomalies of the Kidneys and Urinary Tract). Also several randomized controlled trials on antibiotic prophylaxis in children with VUR have reported conflicting results on its efficacy in preventing UTI and renal damage.\(^3-9\) Newer UTI guidelines were released by the National Institute of Clinical Excellence (NICE)\(^10\) from the UK in 2006, American Academy of Pediatrics (AAP)\(^11\) in 2012, and the Italian\(^12\) and Australian\(^13\) Groups around the same time.

For diagnosis, most groups recommend testing for UTI in all febrile young children. Most groups recommended using clean void urine samples for urinalysis and culture, though AAP accepted only samples from catheterization or suprapubic aspiration. Confirmation of diagnosis depends on presence of symptoms, evidence of inflammation (mostly as pyuria), and significant colony counts on culture. For clean void urine, most took \(10^5\) CFU/ml as significant growth, though lower counts indicate probably UTI if clinically compatible.
For treatment, current guidelines recommend giving antibiotics according to local sensitivity pattern of possible uropathogens. Most often second or third generation cephalosporins or amoxicillin-clavulanic acid can be given for 7-14 days. Randomized controlled trials reported no differences between oral versus full intravenous treatment or initial intravenous with switch to oral versus full intravenous treatment, if the child can tolerate oral treatments and compliance can be ensured.

Major variations in recommendations occur in the imaging strategy after a febrile UTI. The AAP recommends only USG and follow up, and doing VCUG when USG is abnormal or UTI recurs. The NICE, Italian and Australian guidelines recommend, in addition to above, doing VCUG and DMSA scan if a patient has high risk of renal damage, as indicated by risk factors. These factors include having severe illness, septicemia, renal impairment, abdominal mass or poor urine stream on presentation, UTI due to non-E.coli pathogens, and delayed resolution of fever with appropriate antibiotics. Young age below 6 months and a family history of urological abnormalities are also considered risk factors in the NICE and Italian guideline.

In terms of preventive strategy, the AAP does not recommend routine antibiotic prophylaxis, while the NICE guidelines recommend to “consider” antibiotic prophylaxis for recurrent UTI. The Italian and Australian guidelines also recommend prophylaxis in dilating VUR or recurrent UTI.

The local UTI guideline in Hospital Authority has also been revised recently. It recommends no routine VCUG or antibiotic prophylaxis. Similar to the NICE, Italian and Australian Guidelines, the HA guideline recommends VCUG if USG is abnormal or UTI recurs. It also suggests to “consider” VCUG if risk factors are present (see list of risk factors in the full guideline document). In this situation, the risk of missing significant abnormalities which needs treatment versus the potential complications of VCUG such as irradiation, urethral trauma, iatrogenic infection or sedation risks would be discussed with parents, and their preference were followed. Antibiotic prophylaxis would be “considered” in patients with grade III VUR, and “recommended” if such patients have UTI recurrence (second episode). DMSA would be
ordered for VUR of grade III or above. If such a patient has severe renal scarring on DMSA, they would be offered the option of surgical intervention such as Deflux injection after the second UTI. If a patient with gross VUR has a second recurrence (third episode) despite antibiotic prophylaxis, surgical intervention should be recommended.

Interested colleagues should refer to the original articles for the detailed recommendations which were only briefly discussed above.

Reference List


(14) UTI Guideline Development Panel. Clinical Guideline on The Diagnosis and Initial Management of Urinary Tract Infections in Infants and Children aged 2 to 24 months. Hospital Authority, Hong Kong.
Copyright and Disclaimers

Copyright Status

Information that is created by or for the Hong Kong College of Paediatricians (HKCPaed) on this site may be freely distributed and copied. However, it is requested that in any subsequent use of this work, HKCPaed be given appropriate acknowledgment.

**NOTE:** This site contains resources such as, but not limited to, HKCPaed which incorporate material contributed or licensed by individuals, companies, or organizations that may be protected by Hong Kong copyright laws. All persons reproducing, redistributing, or making commercial use of this information are expected to adhere to the terms and conditions asserted by the copyright holder. Transmission or reproduction of protected items beyond that allowed by fair use (PDF) as defined in the copyright laws requires the written permission of the copyright owners.

Disclaimer

**Liability:** For documents and software available from this server, the Hong Kong College of Paediatricians does not warrant or assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed.

**Endorsement:** HKCPaed does not endorse or recommend any commercial products, processes, or services. The views and opinions of authors expressed on this Web site do not necessarily state or reflect those of the HKCPaed, and they may not be used for advertising or product endorsement purposes.

**External Links:** Some HKCPaed Web pages may provide links to other Internet sites for the convenience of users. HKCPaed is not responsible for the availability or content of these external sites, nor does HKCPaed endorse, warrant, or guarantee the products, services, or information described or offered at these other Internet sites. Users cannot assume that the external sites will abide by the same Privacy Policy to which HKCPaed adheres. It is the responsibility of the user to examine the copyright and licensing restrictions of linked pages and to secure all necessary permissions.